We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Myeloma Center

You are here

Advances in immunotherapy in multiple myeloma.

TitleAdvances in immunotherapy in multiple myeloma.
Publication TypeJournal Article
Year of Publication2017
AuthorsBoussi L, Niesvizky R
JournalCurr Opin Oncol
Volume29
Issue6
Pagination460-466
Date Published2017 Nov
ISSN1531-703X
KeywordsCancer Vaccines, Humans, Immunotherapy, Immunotherapy, Adoptive, Multiple Myeloma
Abstract

PURPOSE OF REVIEW: Here, we explore the significant progress made in the treatment of multiple myeloma, focusing on immunotherapy and the promise it has offered to patients suffering from advanced disease.

RECENT FINDINGS: Multiple myeloma, a B-cell malignancy, is characterized by unregulated plasma cell growth in the bone marrow as well as strong immunosuppression in the tumor microenvironment. mAbs targeting tumor antigens overcome this, increasing T-cell activation, multiple myeloma cell death, and depth of response. Similarly, adoptive T-cell therapy aims to engineer or isolate tumor-specific T cells for a targeted approach. Finally, peptide and dendritic cell/tumor fusion vaccines reeducate the immune system, expanding the immune response and generating long-term memory to prevent relapse of disease. Many of these approaches have been combined with existing therapies to enhance antitumor immunity.

SUMMARY: Immunotherapeutic approaches have remarkably changed the treatment paradigm for multiple myeloma, and encouraging patient responses have warranted further investigation into mAbs, adoptive T-cell therapy, vaccines, and combination therapy.

DOI10.1097/CCO.0000000000000407
Alternate JournalCurr Opin Oncol
PubMed ID28877078